参考文献/References:
[1] Goldstraw P,Crowley J,Chansky K,et al.The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming(seventh)edition of the TNM classification of malignant tumours[J].Journal of Thoracic Oncology,2007,2(8):706-714.
[2] Libshitz HI,McKenna RJ,Mountain CF.Patterns of mediastinal metastases in bronchogenic carcinoma[J].Chest,1986,90(2):229-232.
[3] Kirsh MM,Kahn DR,Gago O,et al.Treatment of bronchogenic carcinoma with mediastinal metastases[J].The Annals of Thoracic Surgery,1971,12(1):11-21.
[4] Riquet M,Hidden G,Debesse B.Direct lymphatic drainage of lung segments to the mediastinal nodes.An anatomic study on 260 adults[J].The Journal of Thoracic and Cardiovascular Surgery,1989,97(4):623-632.
[5] Imai K,Minamiya Y,Saito H,et al.Detection of pleural lymph flow using indocyanine green fluorescence imaging in non-small cell lung cancer surgery:a preliminary study[J].Surgery Today,2013,43(3):249-254.
[6] Gorai A,Sakao Y,Kuroda H,et al.The clinicopathological features associated with skip N2 metastases in patients with clinical stage ⅠA non-small-cell lung cancer[J].Eur J Cardiothorac Surg,2015,47(4):653-658.
[7] Okiemy G,Foucault C,Avisse C,et al.Lymphatic drainage of the diaphragmatic pleura to the peritracheobronchial lymph nodes[J].Surg Radiol Anat,2003,25(1):32-35.
[8] Ndiaye A,Di-Marino V,Ba PS,et al.Anatomical variations in lymphatic drainage of the right lung:applications in lung cancer surgery[J].Surg Radiol Anat,2016,38(10):1143-1151.
[9] Misthos P,Sepsas E,Athanassiadi K,et al.Skip metastases:analysis of their clinical significance and prognosis in the ⅢA stage of non-small cell lung cancer[J].Eur J Cardiothorac Surg,2004,25(4):502-508.
[10] Ilic N,Petricevic A,Arar D,et al.Skip mediastinal nodal metastases in the Ⅲa/N2 non-small cell lung cancer[J].J Thorac Oncol,2007,2(11):1018-1021.
[11] Yoo C,Yoon S,Lee DH,et al.Prognostic significance of the number of Metastatic pN2 lymph nodes in stage ⅢA-N2 non-small-cell lung cancer after curative resection[J].Clinical Lung Cancer,2015,16(6):e203-e212.
[12] Yazgan S,Ucvet A,Gursoy S,et al.Single-station skip-N2 disease:good prognosis in resected non-small-cell lung cancer(long-term results in skip-N2 disease)[J].Interact Cardiovasc Thorac Surg,2019,28(2):247-252.
[13] Wang L,Zhan C,Gu J,et al.Role of skip mediastinal lymph node metastasis for patients with resectable non-small-cell lung cancer:a propensity score matching analysis[J].Clinical Lung Cancer,2019,20(3):e346-e355.
[14] Guerrera F,Renaud S,Tabbó F,et al.Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas [J].Eur J Cardiothorac Surg,2017,51(4):680-688.
[15] Sezen CB,Aksoy Y,Sonmezoglu Y,et al.Prognostic factors for survival in patients with completely resected pN2 non-small-cell lung cancer[J].Acta Chir Belg,2019,29:1-7.
相似文献/References:
[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(12):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(12):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(12):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[5]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[6]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(12):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[7]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(12):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[8]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(12):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[9]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(12):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
[10]崔 凯,白峻峰,公孙鑫,等.Wiskott-Aldrich综合征蛋白家族成员3对非小细胞肺癌侵袭转移的影响及机制研究[J].陕西医学杂志,2021,50(12):1505.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.009]
CUI Kai,BAI Junfeng,GONGSUN Xin,et al.Effect and mechanism of WASF3-AS1 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(12):1505.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.009]